About Us

About OncoTEX

OncoTEX is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables the development of pharmaceuticals that are tumor localizing, exhibit low side effects, target both drug-sensitive and drug-resistant solid tumors, and are MRI-detectable.

OncoTEX is developing TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance. OxaliTEX is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer. TEX Core is designed to target tumor cells by overcoming challenges associated with the current platinum-based standards-of-care (SOC).

More than 300,000 women globally are diagnosed with ovarian cancer each year, making ovarian cancer one of the leading causes of cancer-related death in women. This is because ovarian cancer is rarely symptomatic in its early stages and often untreatable by the time of detection. OxaliTEX overcomes platinum resistance and is tumor localizing, well-tolerated, and MRI-detectable to allow clinicians and patients to easily monitor tumor regression. The OncoTEX pipeline consists of several drug candidates at different stages of development for the treatment of multiple cancer indications.

Our Mission

Our mission is to transform current cancer treatments by directly targeting tumors while minimizing toxic side effects of traditional chemotherapy. We are addressing an urgent unmet clinical need with TEX Core, an oncology drug platform designed to treat multiple solid tumor indications.